Late Plasma Cell Depletion After Thymoglobulin Induction in Kidney Transplant Recipients

• Published in: Experimental and clinical transplantation 2019-12, Vol.17 (6), p.732-738
• Main Authors: Irure, Juan, Sango, Cristina, San Segundo, David, Fernández-Fresnedo, Gema, Ruiz, Juan Carlos, Benito-Hernández, Adalberto, Asensio, Esther, López-Hoyos, Marcos, Rodrigo, Emilio
• Format: Article
• Language: English
• Subjects: Tıp
• ISSN: 1304-0855; 2146-8427
• DOI: 10.6002/ect.2018.0261

Objectives: Induction therapy with rabbit antithymocyte globulin is frequently used in kidney transplant recipients and contributes to regulating the humoral alloantibody response. However, the effect of rabbit antithymocyte globulin on B-cell subpopulations, including plasma cells, has not been previously studied in humans in vivo. Materials and Methods: We prospectively studied a cohort of 39 adult kidney transplant recipients. Twenty patients received rabbit antithymocyte globulin as induction therapy. Peripheral blood samples were obtained pretransplant and at 6 and 12 months posttransplant. T and B cells were acquired by flow cytometry. Results: Total lymphocytes and CD3 and CD4 cells significantly decreased at 6 and 12 months only in patients who received rabbit antithymocyte globulin. In contrast, the CD19 population did not change after rabbit antithymocyte globulin induction. One-year circulating plasma cells remained significantly lower than pretransplant levels in patients who received rabbit antithymocyte globulin. We observed sig nificant differences in plasma cell numbers at 12 months after transplant between patients who received rabbit antithymocyte globulin and those patients who did not receive it (median of 5 and interquartile range of 3-17 vs median of 25 and interquartile range of 12-35; P = .001). Conclusions: Rabbit antithymocyte globulin induction leads to a late reduction in the number of circulating plasma cells at 1 year after kidney transplant. This effect can contribute to down-regulation of the humoral alloantibody response.